Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2026-02-13 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Interim / Quarterly Report Classification · 92% confidence The document is a board meeting outcome filed under SEBI Listing Regulations (Reg. 33 & 30) that includes the full Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025, as approved by the Board, along with the Limited Review Report from the auditors. It contains substantive financial statements and detailed notes, not merely a brief highlights announcement. This corresponds to an Interim/Quarterly Report. 9M 2025
2026-02-13 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-02-04 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is an intimation letter addressed to stock exchanges regarding a scheduled Board of Directors meeting to consider unaudited financial results for a quarter and nine months ended December 31, 2025. It references SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 29 and 33, which pertain to disclosures about board meetings and financial results. The document does not contain the financial results themselves but announces the upcoming meeting where these results will be considered. It also mentions the closure of the trading window for insider trading compliance. The document length is short (1788 characters) and serves as a notification rather than a report containing financial data. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories like Interim Report or Earnings Release, which would require actual financial data or results.
2026-02-04 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming details of securities dematerialized/rematerialized for the quarter and nine months ended December 31, 2025. It is a compliance certification addressed to stock exchanges, signed by the company secretary. The document is short (1571 characters) and primarily a regulatory compliance certificate rather than a financial report or announcement. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and certification.
2026-01-16 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 07.01.2026 addressed to stock exchanges, disclosing a regulatory update about Medicamen Biotech Limited receiving EU approval for product registration of 'Paracetamol' from the Danish Medicine Authority. It is filed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document does not contain financial data, detailed reports, or management commentary. It is a regulatory announcement informing the market of a significant event related to product approval. Given the short length (1089 characters) and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-01-07 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of unaudited financial results for the quarter and half year ended September 30, 2025. It references the approval of these results by the Board of Directors and mentions the publication of an extract in newspapers. The document length is short (1346 characters) and it primarily serves as a notification or announcement of the financial results publication rather than containing the full financial statements or detailed analysis itself. According to the 'Menu vs Meal' rule, such a document is an announcement of a report rather than the report itself. Therefore, it should be classified as a Report Publication Announcement (RPA).
2025-11-18 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.